Bringing CAR T cell therapy trials to underserved populations.

Autor:	Badr H; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: hoda.badr@bcm.edu., Rouce R; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. Electronic address: rouce@bcm.edu., Scheurer ME; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA., Lulla P; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Mims M; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Reddy P; Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: pavan.reddy@bcm.edu.
Jazyk:	angličtina
Zdroj:	Cancer cell [Cancer Cell] 2023 Dec 11; Vol. 41 (12), pp. 2007-2010. Date of Electronic Publication: 2023 Oct 26.
DOI:	10.1016/j.ccell.2023.10.002
Abstrakt:	There is a critical need for equitable access to cell therapies in cancer treatment, particularly within public safety-net healthcare systems that serve minority and socioeconomically disadvantaged populations. We discuss how the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is piloting a cell therapy program aimed at addressing cancer care disparities and has the potential to serve as a national model for enhancing health equity in cancer care. Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu